Astellas Pharma Overview and Business Operations

Astellas Pharma is a Japanese pharmaceutical company that has made a significant impact in the industry. Founded in 1923, Astellas has a rich history of innovation and dedication to improving people's lives.

Astellas is headquartered in Tokyo, Japan, and has a global presence with operations in over 70 countries. The company's name is derived from the Japanese word "Astell", which means "star" and "las", which represents the company's commitment to shining a light on new possibilities.

Astellas' business operations are focused on developing and commercializing innovative therapies for a range of diseases, including urology, oncology, and neuroscience. The company's portfolio includes a diverse range of products, from prescription medications to over-the-counter treatments.

Broaden your view: Cassa Centrale Banca - Credito Cooperativo Italiano

Astellas Pharma has its roots in the Yamanouchi Pharmaceutical Co., Ltd., a Japanese pharmaceutical company founded in 1923 by Kiichi Yamanouchi.

The company was initially focused on producing high-quality pharmaceuticals for the Japanese market.

In 1996, Yamanouchi merged with Fujisawa Pharmaceutical Co., Ltd., another Japanese pharmaceutical company, to form Yamanouchi Pharmaceutical Co., Ltd.

This merger created a company with a strong presence in both the Japanese and international markets.

Astellas Pharma was officially established in 2005, when Yamanouchi merged with Kissei Pharmaceutical Co., Ltd. and other companies to form a new entity.

The name "Astellas" comes from the Greek word "asthenia", meaning weakness or lack of energy, which reflects the company's focus on developing treatments for diseases that cause fatigue or weakness.

A fresh viewpoint: Astellas Stock Symbol

Astellas Pharma operates in multiple therapeutic areas, including oncology, nephrology, transplantation, and urology.

The company focuses on developing innovative medicines, which is reflected in its recent acquisitions. In 2023, Astellas acquired IVERIC Bio, Inc. for USD 5.9bn and Propella Therapeutics for USD 175mn.

Revenue-wise, the pharmaceutical segment generated a significant amount of revenue in 2023, totaling ¥1,603.67 billion.

Astellas Pharma Inc has a strong presence in several therapeutic areas, including oncology, nephrology, transplantation, and urology.

Therapeutic areas for the company include oncology, nephrology, transplantation, and urology.

Astellas' product categories focus on innovative medicines, which is a key area of growth for the company.

In 2023, Astellas acquired IVERIC Bio, Inc. for USD 5.9 billion and Propella Therapeutics for USD 175 million.

The company's revenue by segment for 2023 was 1,603.67 billion JPY, primarily driven by pharmaceutical sales.

Here's a breakdown of Astellas' revenue by segment in 2023:

Astellas has also made significant investments in research and development, with priority areas including infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

In 2007, the company narrowed UK distribution of Advagraf and Prograf to a sole distributor, UniChem, in reaction to pharmacist complaints about drug availability from wholesale sources.

This move was a significant change in their distribution strategy. It's interesting to note how companies can adjust their business operations in response to customer feedback.

The sole distributor arrangement was revised in 2010 to include three firms: AAH, Alliance Healthcare, and Phoenix Healthcare Distribution. This change allowed for a broader distribution network in the UK.

The company's decision to expand its distribution network shows how businesses can adapt to changing circumstances and improve their operations.

Readers also liked: Japan Post Network

Astellas Pharma has faced several controversies over the years, including a year-long suspension from the Association of the British Pharmaceutical Industry (ABPI) in 2016.

The suspension was imposed due to complaints that Astellas had "purposely misled the PMCPA" by not fully disclosing the nature of a meeting that was supposed to be a "genuine advisory board".

Astellas was also reprimanded for producing promotional materials that lacked required prescribing information for several medicines.

In 2019, Astellas agreed to pay the United States Department of Justice $100 million to resolve allegations that it had conspired to offer kickbacks via Medicare copay foundations.

Astellas has faced several controversies over the years. In 2016, the Association of the British Pharmaceutical Industry (ABPI) gave Astellas a year-long suspension after complaints it had "purposely misled the PMCPA".

The suspension was extended by a further 12 months in 2017, based on findings that Astellas was not adequately overseeing and training nurses, and that it had failed to provide complete prescribing information for several medicines.

Astellas was reprimanded in June 2017 for producing promotional materials that did not include required prescribing information for eight drugs.

The company was also found to have inappropriately awarded research funding to a senior clinician at a British hospital, leading to a protocol that was later abandoned due to poor outcomes.

In 2019, Astellas agreed to pay the United States Department of Justice $100 million to resolve allegations that it had conspired to offer kickbacks via Medicare copay foundations.

An employee of Astellas was detained in China by authorities in March 2023 for alleged espionage, sparking criticism from the Japanese government.

The World Intellectual Property Organization (WIPO) has a system in place to ensure that intellectual property rights are protected and respected.

In the United States, the Copyright Act of 1976 sets forth the exclusive rights of copyright owners, including the right to reproduce and distribute their work.

The WIPO Copyright Treaty (WCT) requires countries to provide adequate legal protection and remedies for copyright infringement.

On a similar theme: CEE Property Development Portfolio

The Digital Millennium Copyright Act (DMCA) in the United States requires online service providers to remove or disable access to infringing content upon receiving a proper notification.

The European Union's Copyright Directive sets forth a framework for the protection of copyright and related rights in the digital environment.

The EU's Article 17, also known as the "Upload Filter", requires online content sharing service providers to ensure that only authorized content is uploaded and shared.

The EU's Article 15, also known as the "Text and Data Mining" exception, allows for the use of copyrighted materials for research and analysis purposes.

Related reading: Central Illinois Public Service Company

Astellas Pharma is a pharmaceutical company that produces a wide range of products, including medications for various health conditions. Some of their notable products include Adenocard and Adenoscan, which are used as pharmacologic stress agents for myocardial perfusion scans.

Their anti-fungal medications, such as AmBisome, Cresemba, and Mycamine, are also worth mentioning. These medications are used to treat various fungal infections.

See what others are reading: Sumitomo Precision Products

Astellas also produces medications for other health conditions, including plaque psoriasis (Amevive), post-transplant organ rejection (Astagraf XL and Prograf), and atopic dermatitis (Protopic).

Here is a list of some of the products produced by Astellas:

Astellas has a below-average performance in research and development. The company has a small-sized pipeline compared to its peers, which is a concern.

Astellas engages in R&D for priority diseases and non-communicable diseases, but its pipeline is limited. The company has an access planning framework in place, but the breadth and depth of plans are limited.

Astellas has access plans for most late-stage pipeline candidates, but the company does not publicly disclose disaggregated R&D investment data. This lack of transparency makes it difficult to assess the company's R&D efforts.

Astellas has a structured process in place to develop access plans during R&D, which is a positive step. However, the company does not make a public commitment addressing its systematic approach to access planning for LMICs.

Curious to learn more? Check out: Access Bank Tanzania

The company's small-sized priority R&D pipeline has access plans in place for 100% of its late-stage candidates. Astellas focuses on various priority areas, including Chagas disease, leishmaniasis, and schistosomiasis.

Astellas' late-stage candidate targeting a priority product gap has evidence of an access plan, including multiple components. These components include WHO prequalification, a technology transfer agreement, and equitable pricing plans.

The company's small-sized pipeline also addresses other diseases in scope, with 60% of late-stage projects covered by access plans. However, Astellas does not publicly disclose R&D investment data disaggregated by disease category, product type, or phase of development.

Astellas does not engage in R&D capacity building initiatives that meet inclusion criteria. This is a missed opportunity for the company to invest in its R&D capabilities.

Astellas Pharma is a company that's not afraid to make big moves in the pharmaceutical industry. It acquired biotech Iveric Bio for $5.9 billion to accelerate treatments for blinding retinal diseases.

This acquisition is a significant step forward in the development of treatments for retinal diseases. Astellas' goal is to bring new hope to patients suffering from these debilitating conditions.

Astellas has also entered into a definitive agreement to acquire Audentes Therapeutics for $3 billion. This acquisition is a major investment in gene therapy and rare disease treatments.

Astellas' acquisition strategy is clearly focused on expanding its portfolio of treatments and therapies. With these two acquisitions, the company is poised to make a significant impact in the pharmaceutical industry.

Take a look at this: Proposed Acquisition of U.S. Steel by Nippon Steel

Astellas Pharma has received several regulatory approvals and updates for its treatments. Xtandi, a treatment for prostate cancer, was approved by the EC for its third indication in metastatic hormone-sensitive prostate cancer in 2016.

The CHMP issued a positive opinion for a label update of Xtandi, recommending approval of a type II variation to include data from the TERRAIN trial. This update aimed to demonstrate the efficacy and safety of Xtandi versus bicalutamide.

In 2019, the FDA granted priority review to XTANDI's sNDA, seeking to add an indication for men with prostate cancer that's spread but is sensitive to hormone therapy.

The CHMP has recommended approval of a type II variation to include data from the TERRAIN trial of Xtandi.

The TERRAIN trial compared Xtandi to bicalutamide, and we can expect to see the updated label reflecting this new data soon.

Xtandi is a treatment for prostate cancer, and the CHMP's positive opinion is a significant step forward for patients.

The ARCHES trial will also be evaluating the efficacy and safety of Xtandi with androgen deprivation therapy versus placebo with ADT in men with metastatic hormone-sensitive prostate cancer.

The CHMP's decision is a testament to the ongoing efforts to improve treatments for prostate cancer patients.

Xtandi has already been approved for several indications, including metastatic hormone-sensitive prostate cancer, where it reduced the risk of radiographic progression or death by 61 percent in a trial.

This updated label will provide more information to doctors and patients about the benefits and risks of Xtandi.

Broaden your view: NTT Data

A Supplemental New Drug Application has been submitted for roxadustat in Japan to address an unmet clinical need for patients with a particular kind of anaemia.

Roxadustat is being presented as a potential treatment for this type of anaemia in Japan.

Astellas Pharma Inc has several competitors in the market, including Daiichi Sankyo Co Ltd, Eisai Co Ltd, Kyowa Kirin Co Ltd, and Taisho Pharmaceutical Holdings Co Ltd.

These companies are all based in Japan, with headquarters in major cities such as Tokyo and Chuo-Ku.

The number of employees at these companies varies greatly, with Daiichi Sankyo Co Ltd having the most employees at 19,765, followed closely by Astellas Pharma Inc with 13,643.

Here's a comparison of the number of employees at each of these companies:

Astellas Pharma Inc is the only private company in this group, while the others are all publicly traded.

In the world of pharmaceutical companies, it's essential to know who your competitors are and how they stack up. Astellas Pharma Inc, Daiichi Sankyo Co Ltd, Eisai Co Ltd, Kyowa Kirin Co Ltd, and Taisho Pharmaceutical Holdings Co Ltd are all major players in Japan.

Astellas Pharma Inc has a significant presence with 13,643 employees. Daiichi Sankyo Co Ltd has the largest workforce, with 19,765 employees. In contrast, Taisho Pharmaceutical Holdings Co Ltd has a relatively smaller workforce of 8,784 employees.

The entity type of these companies is also worth noting. Astellas Pharma Inc, Daiichi Sankyo Co Ltd, Eisai Co Ltd, and Kyowa Kirin Co Ltd are all public companies, while Taisho Pharmaceutical Holdings Co Ltd is a private company.

Here's a comparison of the companies' headquarters:

Sales Forecasts are a crucial aspect of any business, and in the pharmaceutical industry, they can make or break a company's success. For Astellas Pharma Inc, their sales forecasts are looking promising, especially with their top-selling product Xtandi, which is used to treat Prostate Cancer.

Xtandi, also known as Izervay, is expected to continue its dominance in the market, with sales forecasts indicating a steady increase in revenue over the next 8 years. In fact, the patient population for Prostate Cancer is expected to grow significantly, providing a huge market opportunity for Astellas Pharma Inc.

Their other top-selling product, Xospata, used to treat Acute Myeloid Leukemia, is also showing strong sales forecasts. Although it's not as dominant as Xtandi, Xospata is still expected to contribute significantly to the company's revenue.

Here's a breakdown of Astellas Pharma Inc's top-selling products and their sales forecasts:

Overall, Astellas Pharma Inc's sales forecasts are looking positive, with their top-selling products expected to continue their success in the market.

Astellas Pharma has a commercialized product portfolio that includes marketed drugs.

Fezolinetant is a non-hormonal treatment being evaluated for severe vasomotor symptoms associated with menopause in a Phase III trial.

The safety of fezolinetant was shown in the Phase III study, which involved over 1,800 women.

Cresemba, also known as isavuconazonium sulfate, is an azole antifungal used to treat invasive aspergillosis and invasive mucormycosis in patients 18 years of age and older.

Astellas Pharma Inc has a diverse commercialized product portfolio that includes marketed drugs.

One of these drugs is Propecia, used to treat male pattern hair loss.

Propecia is available in tablet form and is taken once daily.

Another marketed drug from Astellas is Myrbetriq, which is used to treat overactive bladder symptoms.

Myrbetriq works by relaxing the muscles in the bladder to improve urine flow and reduce symptoms.

Fezolinetant has been shown to be a safe non-hormonal treatment option for women experiencing severe vasomotor symptoms associated with menopause.

A Phase III study of over 1,800 women is evaluating the safety and efficacy of fezolinetant.

The study is focused on providing relief from severe VMS, a common symptom of menopause that can be debilitating for many women.

This research is a significant step forward in finding effective treatments for women struggling with menopause symptoms.

The study's large participant pool of over 1,800 women is a testament to the need for safe and effective treatments like fezolinetant.

Cresemba is an azole antifungal used to treat invasive mucormycosis and invasive aspergillosis in patients 18 years and older.

The study data for Cresemba in patients with mucormycosis has been published, providing valuable insights into its effectiveness.

Cresemba is specifically indicated for the treatment of invasive mucormycosis in patients 18 years of age and older.

Astellas Pharma has a rich history of leadership and milestones that have shaped the company into what it is today. Founded in 1923, Astellas has been a leader in the pharmaceutical industry for nearly a century.

The company has a strong track record of innovation, with a focus on developing medicines that improve the lives of patients. In 2005, Astellas merged with Yamanouchi Pharmaceutical to create a global biopharmaceutical company.

Astellas has a presence in over 70 countries worldwide, with a diverse portfolio of products and a commitment to delivering value to patients, customers, and shareholders. The company has a strong leadership team, with a CEO who has been at the helm since 2014.

Under its current leadership, Astellas has made significant strides in expanding its global presence and developing new treatments for diseases such as cancer and urology. The company has also made a commitment to sustainability and social responsibility.